Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 28, 2016

View Archived Issues

Eisai and OMRF form research collaboration to study lupus

Prometic Life Sciences reports positive data in phase II/III trial of IV plasminogen

SBI signs license agreement with Neopharma for 5-ALA in diabetes and malaria

Dong-A ST and Beactica sign drug discovery collaboration and licensing agreement

Targeting oligosaccharyltransferase with novel compound shows promise against lung cancer cells

Adamas Pharmaceuticals submits NDA for ADS-5102

ProQR Therapeutics' study of QR-010 in CF meets primary endpoint

ChemoCentryx's CCX-168 leads to improvements in patient with C3 glomerulopathy

FDA places partial clinical hold on enrollment in durvalumab trials for head and neck cancer

Allergan exercises option to acquire Motus Therapeutics

Fluxion launches Spotlight 59 Oncology Panel

Janssen Research & Development announces launch of ACCELERATE registry for Castleman disease

First phase IIa trial of Medivir's MIV-711 fully enrolled, cleared to procede

Shanghai Huilun Life Science & Technology patents PARP-1 inhibitors

Gedeon Richter patents MCH1 receptor antagonists

Eisai reports FGFR-4 inhibitors for liver cancer

Dana-Farber Cancer Institute patent describes CDK inhibitors

Plexxikon divulges FLT3 mutant inhibitors for leukemia

Levo agrees terms with Ferring for worldwide rights to carbetocin for Prader-Willi syndrome

FDA approves Roche's Ventana PD-L1 assay as complementary diagnostic for atezolizumab in NSCLC

Cellid initiates phase I trial of BVAC-C for cervical cancer

Adaptimmune and MSD to evaluate Keytruda in combination with NY-ESO SPEAR in multiple myeloma

Alexion initiates registration trials for ALXN-1210 in PNH and aHUS

EMA accepts for review MAA for niraparib in ovarian cancer

Technische Universitaet Muenchen describes novel, selective PET tracer for alpha-synucleinopathies

Novel radiotracer from Avaant Pharmaceuticals may detect multidrug resistance

Novartis reports pipeline highlights of third quarter 2016

Chemotherapy enhances immunotherapy with ISA-101 in cervical cancer trial

Chugai recaps milestones of third quarter 2016

PD-L1 inhibitor atezolizumab successfully combined with MEK and BRAF inhibitors in melanoma trial

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
Deals and an M&A strengthen end-of-year numbers
BioWorld
Two large deals and an acquisition, totaling about $4.64 billion in all, are helping wrap up what’s turning out to be a strong year. Through the first 11 months...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
Radiopharm Theranostics’ RAD-101 meets brain metastases endpoints
BioWorld
Radiopharm Theranostics Ltd.’s radiotracer RAD-101 met the primary endpoint in 92% of patients in the phase IIb imaging trial in brain metastases, according to...